Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

The risk of oesophageal adenocarcinoma in a prospectively recruited Barrett's oesophagus cohort.

Theron BT, Padmanabhan H, Aladin H, Smith P, Campbell E, Nightingale P, Cooper BT, Trudgill NJ.

United European Gastroenterol J. 2016 Dec;4(6):754-761. doi: 10.1177/2050640616632419. Epub 2016 Feb 19.

2.

Trends and predictions for gastric cancer mortality in Brazil.

de Souza Giusti AC, de Oliveira Salvador PT, Dos Santos J, Meira KC, Camacho AR, Guimarães RM, Souza DL.

World J Gastroenterol. 2016 Jul 28;22(28):6527-38. doi: 10.3748/wjg.v22.i28.6527.

3.

Unique Clinicopathology of Proximal Gastric Carcinoma: A Critical Review.

Huang Q.

Gastrointest Tumors. 2014 Aug;1(3):115-22. doi: 10.1159/000365305. Epub 2014 Jul 18. Review.

4.

Reciprocal impact of host factors and Helicobacter pylori genotypes on gastric diseases.

Honarmand-Jahromy S, Siavoshi F, Malekzadeh R, Nejad Sattari T, Latifi-Navid S.

World J Gastroenterol. 2015 Aug 21;21(31):9317-27. doi: 10.3748/wjg.v21.i31.9317.

5.

Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.

Whitson MJ, Falk GW.

Gastroenterol Clin North Am. 2015 Jun;44(2):299-315. doi: 10.1016/j.gtc.2015.02.005. Epub 2015 Mar 31. Review.

6.

Sex and race and/or ethnicity differences in patients undergoing radiofrequency ablation for Barrett's esophagus: results from the U.S. RFA Registry.

Pasricha S, Li N, Bulsiewicz WJ, Rothstein RI, Infantolino A, Ertan A, Camara DS, Dellon ES, Triadafilopoulos G, Lightdale CJ, Madanick RD, Lyday WD, Muthusamy RV, Overholt BF, Shaheen NJ.

Gastrointest Endosc. 2015 Aug;82(2):276-84. doi: 10.1016/j.gie.2015.01.015. Epub 2015 Apr 1.

7.

Republished: symptomatic reflux disease: the present, the past and the future.

Boeckxstaens G, El-Serag HB, Smout AJ, Kahrilas PJ.

Postgrad Med J. 2015 Jan;91(1071):46-54. doi: 10.1136/postgradmedj-2013-306393rep.

8.

Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention.

Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F.

Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):700-13. doi: 10.1158/1055-9965.EPI-13-1057. Epub 2014 Mar 11. Review.

9.

Symptomatic reflux disease: the present, the past and the future.

Boeckxstaens G, El-Serag HB, Smout AJ, Kahrilas PJ.

Gut. 2014 Jul;63(7):1185-93. doi: 10.1136/gutjnl-2013-306393. Epub 2014 Mar 7. Review.

10.

The changing face of esophageal cancer.

Melhado RE, Alderson D, Tucker O.

Cancers (Basel). 2010 Jun 28;2(3):1379-404. doi: 10.3390/cancers2031379.

11.

Risk of esophagus cancer in diabetes mellitus: a population-based case-control study in Taiwan.

Cheng KC, Chen YL, Lai SW, Tsai PY, Sung FC.

BMC Gastroenterol. 2012 Dec 12;12:177. doi: 10.1186/1471-230X-12-177.

12.

Ethnicity in relation to incidence of oesophageal and gastric cancer in England.

Coupland VH, Lagergren J, Konfortion J, Allum W, Mendall MA, Hardwick RH, Linklater KM, Møller H, Jack RH.

Br J Cancer. 2012 Nov 20;107(11):1908-14. doi: 10.1038/bjc.2012.465. Epub 2012 Oct 11.

13.

Patient-centered, comparative effectiveness of esophageal cancer screening: protocol for a comparative effectiveness research study to inform guidelines for evidence-based approach to screening and surveillance endoscopy.

Kramer JR, Arney J, Chen J, Richardson P, Duan Z, Street RL Jr, Hinojosa-Lindsey M, Naik AD, El-Serag HB.

BMC Health Serv Res. 2012 Aug 28;12:288. doi: 10.1186/1472-6963-12-288.

14.

Differential proteomic analysis of noncardia gastric cancer from individuals of northern Brazil.

Leal MF, Chung J, Calcagno DQ, Assumpção PP, Demachki S, da Silva ID, Chammas R, Burbano RR, de Arruda Cardoso Smith M.

PLoS One. 2012;7(7):e42255. doi: 10.1371/journal.pone.0042255. Epub 2012 Jul 30.

15.

Biodegradable esophageal stent placement does not prevent high-grade stricture formation after circumferential mucosal resection in a porcine model.

Pauli EM, Schomisch SJ, Furlan JP, Marks AS, Chak A, Lash RH, Ponsky JL, Marks JM.

Surg Endosc. 2012 Dec;26(12):3500-8. doi: 10.1007/s00464-012-2373-6. Epub 2012 Jun 9.

16.

The association between Barrett's esophagus and Helicobacter pylori infection: a meta-analysis.

Fischbach LA, Nordenstedt H, Kramer JR, Gandhi S, Dick-Onuoha S, Lewis A, El-Serag HB.

Helicobacter. 2012 Jun;17(3):163-75. doi: 10.1111/j.1523-5378.2011.00931.x. Epub 2012 Mar 20.

17.

Incidence and survival of oesophageal and gastric cancer in England between 1998 and 2007, a population-based study.

Coupland VH, Allum W, Blazeby JM, Mendall MA, Hardwick RH, Linklater KM, Møller H, Davies EA.

BMC Cancer. 2012 Jan 12;12:11. doi: 10.1186/1471-2407-12-11.

18.

Risk factors for neoplastic progression in Barrett's esophagus.

Wiseman EF, Ang YS.

World J Gastroenterol. 2011 Aug 28;17(32):3672-83. doi: 10.3748/wjg.v17.i32.3672. Review.

19.

Fascin and CK4 as biomarkers for esophageal squamous cell carcinoma.

Takikita M, Hu N, Shou JZ, Giffen C, Wang QH, Wang C, Hewitt SM, Taylor PR.

Anticancer Res. 2011 Mar;31(3):945-52.

20.

Targeted therapies for metastatic esophagogastric cancer.

Reddy D, Wainberg ZA.

Curr Treat Options Oncol. 2011 Mar;12(1):46-60. doi: 10.1007/s11864-011-0138-4. Review.

Supplemental Content

Support Center